A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 2 SUPPL., 2004, Pages 196-204

  Coleman, Paul G ^a   Morel, Chantal ^a   Shillcutt, Sam ^b,c   Goodman, Catherine ^a   Mills, Anne J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; FANSIDAR;

AFRICA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; GROWTH RATE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MALARIA; MONTE CARLO METHOD; RISK ASSESSMENT;

PROTOZOA;

EID: 4344610138     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.196     Document Type: Conference Paper

References (21)

1. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, 1999. Viewpoint: averting a malaria disaster. Lancet 353: 1965-1967.
2. Bloland PB, Kazembe PN, Oloo AJ, Himonga B, Barat LM, Ruebush TK, 1998. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Trop Med Int Health 3: 543-552.
3. Bloland PB, Ettling M, Meek S, 2000. Combination therapy for African malaria: hype or hope? Bull World Health Organ 78: 1378-1388.
4. McIntosh HM, Olliaro P, 2002. Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database Systematic Review.
5. White NJ, 1999. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41: 301-308.
6. Hastings IM, Watkins WM, White NJ, 2002. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 357: 505-519.
7. Kindermans JM, Pécoul B, Perez-Casas C, Den Boer M, Berman D, Cox I, 2002. Changing National Malaria Treatment Protocols in Africa: What Is the Cost and Who Will Pay? Médicins sans Frontières Campaign for Access to Essential Medicines. Background Paper for the Roll Back Malaria Partnership Meeting on Improving Access to Antimalarial Treatment. Geneva: World Health Organization. September 30 to October 2.
8. Bloland PB, 2001. Drug Resistance in Malaria. Geneva: World Health Organization.
9. Goodman CA, Coleman PG, Mills A, 2001. Changing the first line drug for malaria treatment - cost-effectiveness with highly uncertain inter-temporal trade-offs. Health Econ 10: 731-749.
10. WHO/CTD, 1996. Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria with Intense Transmission. Geneva: World Health Organization. WHO/MAL/96.1077
11. Goodman CA, Coleman PG, Mills A, 1999. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 354: 378-385.
12. Murray CJL, Lopez AD, 1996. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press.
13. Goodman CA, Coleman PG, Mills A, 2000. Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: World Health Organization. Global Forum for Health Research.
14. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B, 2003. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361: 1174-1181.
15. WHO, 1996. Investing in Health Research and Development: Report of the Ad Hoc Committee in Health Research Relating to Future Intervention Options. Geneva: World Health Organization. TDR/Gen/96.1.
16. Curtis CF, Otoo LN, 1986. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg 80: 889-892.
17. Hastings IM, D'Alessandro U, 2000. Modelling a predictable disaster: the rise and spread of drug-resistant malaria. Parasitol Today 16: 340-347.
18. Phillips M, Phillips-Howard PA, 1996. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics 10: 225-238.
19. Sudre P, Breman JG, McFarland D, Koplan JP, 1992. Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis. Int J Epidemiol 21: 146-154.
20. Claxton K, 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18: 341-364.
21. Kindermans JM, 2002. ACTs: Availability and Prices. Geneva: World Health Organization. Presentation at Roll Back Malaria Partners Meeting, October 1.